Call Us

ARTICLES

Arthrosamid®’s story started two decades ago. The brainchild of the team at Contura, the product had been in human use for various indications since 2000, and a favourable safety profile had already been established.

IRELAND’S ORTHOPAEDICS MARKET IS SET TO EMBRACE ‘INNOVATIVE AND EXCITING’ TREATMENT TO HELP EASE PAIN CAUSED BY KNEE OSTEOARTHRITIS

Arthrosamid is a polyacrylamide hydrogel developed by Contura International Ltd. as a long-lasting intra-articular injection approved in Europe for the treatment of knee osteoarthritis (OA). The treatment has the potential to change the present care pathway for managing osteoarthritis, which affects around one in four adults in Ireland aged over 601 (over 400,000 people)2 and current treatments are not long lasting or involve invasive knee replacement surgery. Despite a large suffering population, there has been very little innovation in the range of osteoarthritis treatments on offer to meaningfully help patients – until now.

Why Knee Osteoarthritis Remains Incurable Despite Therapeutic Advancements

Knee osteoarthritis, a common condition causing chronic pain and reduced mobility, remains incurable due to the unique avascular biology of knee cartilage and limited self-repair capacity. Despite advancements in stem cell and gene therapies, current treatments primarily offer symptom relief rather than full cartilage restoration. The disease’s progressive nature, complex causes, and patient variability further complicate effective treatment development. Regulatory and clinical hurdles delay the transition of promising therapies to clinical use. Ongoing research focuses on innovative, personalized approaches to stimulate cartilage repair and overcome these challenges, offering hope for future breakthroughs that could transform management and quality of life for millions affected worldwide.

Read More »

Assessing the Clinical Impact of Arthrosamid on Medial-Compartment Knee Osteoarthritis: Mechanisms, Efficacy, Safety and Future Directions

Arthrosamid® is a novel polyacrylamide hydrogel injection offering targeted, long-lasting relief for medial-compartment knee osteoarthritis, affecting millions worldwide. Unlike traditional treatments, Arthrosamid® delivers mechanical cushioning and improved joint lubrication through a single outpatient procedure, reducing pain and enhancing mobility. Clinical studies report significant symptom improvement lasting up to two years with minimal side effects, bridging the gap between medication and surgery. Ideal for patients unresponsive to conservative therapies, Arthrosamid® supports knee stability and quality of life. Ongoing research aims to validate long-term benefits and explore synergy with regenerative treatments, making Arthrosamid® a promising advancement in osteoarthritis care.

Read More »